M. Knoepfelmacher et al., RESISTANCE TO VASOPRESSIN ACTION ON THE KIDNEY IN PATIENTS WITH CUSHINGS-DISEASE, European journal of endocrinology, 137(2), 1997, pp. 162-166
Objective: To assess the plasma levels and action of arginine vasopres
sin (AVP) in patients with Gushing's disease. There are many reports t
hat patients with Addison's disease have increased AVP levels associat
ed with hyponatraemia and hypoosmolality, but none on the dynamics of
secretion of this neurohormone during osmolality-based stimulation in
patients with chronic hypercortisolism. Design and subjects: The plasm
a AVP concentration and the urinary and plasma osmolality after a 7.5-
h water deprivation test (WDT) were evaluated in 13 patients with Gush
ing's disease and 15 normal (control) individuals. In patients with Gu
shing's disease we also assessed the urinary osmolality in response to
10 mu g i.v. desmopressin (DDAVP) administered at the end of the WDT.
Results: At the end of the WDT, urinary osmolality was significantly
lower in patients with Gushing's disease (511.5+/-148.5 mOsm/l) than i
n the normal subjects (981.1+/-107.1 mOsm/l, P<0.001), whereas plasma
osmolality did not differ between the two groups. Consequently, the ur
ine/plasma osmolality ratio (U-osm/P-osm) was lower in patients with G
ushing's disease than in normal individuals (1.8+/-0.5 compared with 3
.4+/-0.4, P<0.001). The AVP concentration also was greater (7.3+/-3.1
pmol/l) in those with Gushing's disease than in the controls (3.3+/-2.
3 pmol/l, P<0.005). After administration of DDAVP to the hypercortisol
aemic patients, the urinary osmolality attained (718.0+/-200.0 mOsm/l)
was Still lower than that in the normal group al the end of WDT (P<0.
005). Conclusions: Patients with Gushing's disease presented higher AV
P levels and smaller U-osm/P-osm ratios than normal subjects. After DD
AVP, the patients with Gushing's disease were unable to concentrate th
e urine adequately. These data suggest that the kidney shows resistanc
e to the action of both endogenous and exogenous AVP in patients with
Gushing's disease.